NCT06334900

Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 100 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

Glutamic acid decarboxylase (GAD) is an enzyme whose function in the body is to decarboxylate glutamate to GABA. GAD65 antibodies (GAD65Ab) have been associated with type-1 diabetes (80% of new-onset patients) and various neurological conditions, mainly stiff-person syndrome (SPS/PERM), cerebellar ataxia (CA), limbic encephalitis (LE) and temporal lobe epilepsy. These syndromes all seem to result from a reduced transmission of GABA. These neurological conditions are rare and can cause symptoms like confusion, memory loss, muscle stiffness, muscle spasms, behavioural disorders, and pharmacoresistant epilepsy. When finding high levels of GAD65-Ab in the serum, a cerebrospinal fluid (CSF) sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms.

Conditions

• GAD-receptor Antibodies-associated Encephalitis

Interventions

Type	Name	Description
OTHER	GAD patients	Describe the clinical and demographic characteristics of patients with anti-GAD65 antibody associated cerebellar ataxia.

Timeline

• Start date: 2023-10-01
• Primary completion: 2024-01-01
• Completion: 2024-06-30
• First posted: 2024-03-28
• Last updated: 2024-03-28

Locations

1 site across 1 country: France